Abstract:Objectives. The aim of this study is to investigate the effect of glucocorticoids in adult patients with acute respiratory distress syndrome (ARDS) by meta-analysis. Methods. PubMed, Cochrane Library, Embase, CNKI, Wanfang Database, and Chinese Biomedical literature database were searched. A randomized controlled trial (RCTS) on glucocorticoid therapy in adult patients with ARDS was conducted from the time of database construction to December 2021. The content is about the randomized controlled trial (RCT) of glucocorticoid treatment for adult patients with ARDS, without limiting the dose and course of glucocorticoid treatment. The quality of the included RCTS was evaluated by using the bias risk assessment tool of the Cochrane Collaboration network, and the basic information, clinical features, and target outcomes of the literature were extracted. The effects of glucocorticoids on mortality and oxygenation index (PaO2/FiO2) in adult ARDS patients were evaluated by meta-analysis. Results. A total of 1,441 ARDS patients in 10 RCTs were finally included, including 734 patients in the glucocorticoid treatment group (hormone group) and 707 patients in the conventional treatment group (control group). The 10 studies included have a good overall design and high quality. Compared with controls, glucocorticoid use was significantly associated with a decrease in mortality in adult ARDS patients (relative risk (RR) = 0.73, 95% confidence interval (95% CI) = 0.59–0.90, P = 0.003 ). Analysis showed that glucocorticoids significantly reduced the mortality in ARDS patients treated with medium and low doses of steroids (RR = 0.73, 95% CI = 0.58–0.92, P = 0.007 ). In patients with early administration of steroids, intervention with glucocorticoids was significantly associated with the decreased mortality in adult ARDS patients compared with controls (RR = 0.74, 95% CI 0.56–0.99, P = 0.04 ). Among patients with more than 7 days of hormone therapy, treatment with glucocorticoids was significantly associated with decreased mortality in adult ARDS patients (RR = 0.66, 95% CI = 0.50–0.88, P = 0.005 ) compared with controls. Glucocorticoids tended to improve PaO2/FiO2 in adult ARDS patients compared with controls, but the difference was not statistically significant (weighted mean difference (WMD) = 11.60, 95% = CI = 15.02–38.22, P = 0.39 ). Conclusion. Glucocorticoid therapy can reduce mortality in adult ARDS patients, and the benefit is more pronounced in patients with medium- and low-dose hormone therapy, early hormone administration, and hormone therapy for more than 7 days. However, no improvement in PaO2/FiO2 by glucocorticoid treatment was found, which needs to be confirmed by further studies.

The Effectiveness of Corticosteroids on Mortality in Patients with Acute Respiratory Distress Syndrome or Acute Lung Injury: a Secondary Analysis

The Controversy about the Effects of Different Doses of Corticosteroid Treatment on Clinical Outcomes for Acute Respiratory Distress Syndrome Patients: an Observational Study

Decreased mortality in acute respiratory distress syndrome patients treated with corticosteroids: an updated meta-analysis of randomized clinical trials with trial sequential analysis

Clinical outcomes of corticosteroid administration for acute respiratory distress syndrome in adults based on meta-analyses and trial sequential analysis

Corticosteroid in Non-Covid-19 Induced Community-Acquired Pneumonia, a Meta-Analysis.

Meta-Analysis of the Effect of Glucocorticoids on Adult Acute Respiratory Distress Syndrome

Efficacy of corticosteroids in patients with acute respiratory distress syndrome: a meta-analysis

Effects of the working experience, educational background, professional titles, and hospital grades of intensive care unit doctors on clinical glucocorticoid use in acute respiratory distress syndrome

Efficacy and Safety of Methylprednisolone Against Acute Respiratory Distress Syndrome

Efficacy of corticosteroid treatment for severe community-acquired pneumonia: A meta-analysis.

Efficacy and safety of methylprednisolone against acute respiratory distress syndrome A systematic review and meta-analysis

Corticosteroids Treatment in Acute Respiratory Distress Syndrome

Glucocorticoids for acute respiratory distress syndrome: A systematic review with meta‐analysis and trial sequential analysis

Efficacy and safety of corticosteroids for septic shock in immunocompromised patients: A cohort study from MIMIC

Early High Dose Corticosteroid Therapy in Hematopoietic Stem Cell Transplantation Patients with Acute Respiratory Distress Syndrome: a Propensity Score Matched Study

Effect of Low‐to‐moderate‐dose Corticosteroids on Mortality of Hospitalized Adolescents and Adults with Influenza A(H1N1)pdm09 Viral Pneumonia

Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis

The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis

Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome

Analysis of Risk Factors of Mortality for Patients with Acute Respiratory Distress Syndrome

[The Effect of Stress Dose Glucocorticoid on Patients with Acute Respiratory Distress Syndrome Combined with Critical Illness-Related Corticosteroid Insufficiency].